Compare NBY & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | GLMD |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.6M |
| IPO Year | 2007 | 2014 |
| Metric | NBY | GLMD |
|---|---|---|
| Price | $2.77 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 467.3K | ★ 6.3M |
| Earning Date | 11-07-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $10,302,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $114.24 | ★ N/A |
| Revenue Growth | ★ 390.34 | N/A |
| 52 Week Low | $0.46 | $0.74 |
| 52 Week High | $4.44 | $3.61 |
| Indicator | NBY | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 85.94 | 46.71 |
| Support Level | $1.00 | $1.02 |
| Resistance Level | $1.11 | $0.99 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | 0.21 | 0.02 |
| Stochastic Oscillator | 90.14 | 60.50 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.